Everything below reports findings from cell cultures, isolated tissue and animals. This material is for research use only, not for human or veterinary use.
A single number explains most of what follows. CoQ10, also written as coenzyme Q10, has a calculated logP of 19.4, which places it among the most hydrophobic molecules anyone tries to dissolve.
Everything downstream is a consequence. Absorption is slow, saturable and dominated by formulation. Plasma concentration can rise and then plateau. Tissue is another question.
Rodents received the compound for life. Plasma and liver went up several fold, and heart, kidney and brain did not move at all [2]. Indexed adult biopsy and cardiac papers exist [5][14] and [15]. Those human endpoints sit outside the scope of this profile.
Chemical identity
A benzoquinone head on a ten-unit isoprenoid tail, which is where the number in the name comes from.
| Property | Value |
|---|---|
| Systematic name | 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
| INN | Ubidecarenone |
| Common names | CoQ10, coenzyme Q10, ubiquinone |
| Molecular formula | C59H90O4 |
| Molecular weight | 863.3 g/mol |
| Monoisotopic mass | 862.6839 Da |
| CAS number | 303-98-0 |
| PubChem CID | 5281915 |
| InChIKey | ACTIUHUUMQJHFO-UPTCCGCDSA-N |
| Calculated logP | 19.4 |
| Isoprene units | 10 |
| Reduced form | Ubiquinol, C59H92O4, 865.4 g/mol |
| Reduced form CID | 9962735 |
Reading the structure
Two halves do two different jobs, and neither one helps the molecule dissolve.
The quinone head carries the redox chemistry. It accepts and donates electrons in two single-electron steps, passing through a semiquinone radical on the way.
The tail is 50 carbons of polyisoprene. It anchors the molecule inside membranes and gives it lateral mobility there. It is also the reason a gram of powder will not go into water.
PubChem CID 5281915 is the oxidised all-trans form. A cis-contaminated synthetic lot can share the formula and fail a chromatographic isomer check.
Ubiquinone and ubiquinol
The oxidised and reduced forms differ by two hydrogen atoms and by two hydroxyl groups replacing two ketones.
Ubiquinone is the quinone. Ubiquinol is the hydroquinone, and it is the form that acts as a lipid-phase antioxidant. Cells interconvert them continuously as part of normal function.
That interconversion matters on a label, because both forms sell as separate products. What the absorption chemistry says about that distinction appears below.
What it does in a mitochondrion
The textbook role understates the range, and a 2023 review in Trends in Biochemical Sciences is the current summary [16].
The electron carrier role
Complex I and complex II both hand electrons to the same mobile carrier, which then delivers them to complex III.
That junction is the point of the molecule. It is a conduit through which electrons from many pathways enter the respiratory chain, including fatty acid oxidation, dihydroorotate dehydrogenase and others [16].
Because it is the shared entry point, its concentration in the inner membrane is a plausible rate limit. That plausibility is the entire rationale for adding it to a dish, and it is why tissue concentration rather than plasma concentration is the number that matters.
The antioxidant role
The reduced form is a chain-breaking antioxidant within lipid membranes, and few molecules are positioned to do that job.
Ubiquinol intercepts lipid peroxyl radicals in the membrane phase where water-soluble antioxidants cannot reach. It also regenerates alpha-tocopherol, which links the two systems.
The 2023 review adds more roles [16]. They include cofactor duty in biosynthetic and catabolic reactions, detoxification of damaging lipid species, and involvement in cellular signalling and oxygen sensing. Open questions on biosynthesis and transport remain, and the authors name those gaps.
The absorption problem
An 863 Da lipid with a logP near 19 is a difficult oral molecule, and the pharmacokinetic literature reflects that.
A saturable, plateauing curve
Bhagavan and Chopra collated plasma responses across formulations (PMID 17482886).
Total plasma concentration and net increase over baseline both rose with dose, then plateaued. Absorption efficiency fell as the dose rose [3].
Read that as chemistry. Doubling a weigh-out does not double the dissolved exposure, and above a certain point extra solid adds nothing measurable to plasma. This profile does not reprint those milligram ladders as a protocol.
Why formulation dominates
The compound is crystalline at room temperature, and crystals do not absorb.
Mantle and Dybring review the absorption pathway from stomach transit through lymphatic uptake [11]. They place particular weight on crystal dispersion in the original formulation. Their figure is that absence of dispersion reduces bioavailability by 75%.
One caveat belongs with that number. Both authors are employees of a company that manufactures CoQ10 preparations, which the paper discloses. The mechanism is uncontroversial and the specific figure comes from an interested source.
Lymphatic uptake follows from the logP. A molecule this hydrophobic rides chylomicrons. Aqueous buffer work therefore needs a carrier: ethanol or DMSO stocks with vehicle controls, cyclodextrin complexation, or lipid dispersion. Any of those changes what the cells receive.
The ubiquinol question
Marketing for the reduced form rests on a claim that one measurement undercuts.
About 95% of circulating CoQ10 already exists as ubiquinol, and that ratio shows no appreciable change after ingesting the compound [3]. Whichever form goes in, the body decides the redox state of what circulates.
The same logic appeared in the methylcobalamin literature, where cells strip and discard the supplemental methyl group before rebuilding their own cofactors. Here the parallel is exact: the redox form is set after absorption, not by the label.
Solubilised formulations of both forms do show better plasma responses than crystalline preparations [3]. So the useful distinction is dispersion, not oxidation state.
Colour still matters on receipt. Oxidised material is orange-yellow. Reduced material is close to white. A jar sold as ubiquinol that arrives orange has oxidised on the shelf.
Plasma is not tissue
Every supplementation study reports plasma because plasma is easy. Two studies measured what actually matters.
| Study | Model | What moved | What did not |
|---|---|---|---|
| Lönnrot 1998 [2] | Rats and mice, lifelong, 10 mg/kg/day | Plasma and liver, 2.6 to 8.4 fold | Heart, kidney, brain |
| Dohlmann 2022 [15] | Indexed adult biopsy paper | Plasma is not the story | Muscle content in that file |
| Bhagavan 2007 [3] | Collated plasma responses | Plasma, then a plateau | Tissue, not measured |
| Kalén 1989 [1] | Rat and human organs | Age-related lipid composition | A dosing protocol |
The lifelong rodent experiment
Lönnrot and colleagues supplemented Sprague-Dawley rats and C57 mice for their entire lives at 10 mg/kg daily [2].
Plasma and liver concentrations ran 2.6 to 8.4 times higher than controls at every age point. Kidney, heart and brain showed no change in either Q10 or the rodent-dominant Q9.
Survival did not change either. Lifelong supplementation neither extended nor shortened lifespan in either species, and histopathology across tissues showed no differences [2].
That is the cleanest tissue result in the file. Liver takes the lipid. Heart, kidney and brain do not, at that rodent load, for a lifetime.
Indexed biopsy and cardiac papers
Dohlmann and colleagues took the tissue question into people with biopsies rather than blood draws [15]. This profile does not quote their milligram-per-day figure or their symptom scales. The paper exists. The human endpoints sit outside this page.
A later systematic review pooled cardiac trials and ran a statin-interaction meta-regression [14]. Oleck and Ventura reviewed the heart-failure file [8]. Q-SYMBIO and related outcome papers sit in the same list [4][5] and [17]. Parkinson-disease work sits there too [6]. This page leaves those endpoints unread.
Kalén and colleagues measured ubiquinone across organs and found an age-related composition change [1]. That is a tissue-chemistry paper. It is not a reason to write a protocol.
Indexed statin papers
Statins inhibit HMG-CoA reductase, which sits upstream of both cholesterol and the isoprenoid tail. Lower plasma CoQ10 during statin therapy is well documented as a measurement. Whether anything in muscle changes is a separate question.
Where the depletion figure comes from
Two mechanisms produce the same plasma measurement, and only one of them is a tissue deficiency.
The mevalonate pathway supplies the polyisoprenoid tail, so blocking it can reduce synthesis. Circulating CoQ10 also travels in lipoproteins, so a drug that lowers LDL lowers the carrier and the cargo together.
Distinguishing those requires tissue measurement rather than a plasma number. That distinction is exactly what the indexed biopsy paper asked [15].
Pooled analyses stay in the list
Banach, Qu and Wei each pooled creatine-kinase and symptom papers [7][9] and [13]. Derosa added a liquid-preparation paper [10]. Claxton pooled the heart-failure file [14]. This profile does not quote their scales, their creatine-kinase deltas, or their milligram figures.
Note the chemistry that survives those files. Plasma is the easy compartment. Muscle is the hard one. Crystal dispersion dominates the first. The second still looks like the rodent heart and brain: often unchanged [2][15].
Genetic deficiency as a delivery lesson
One setting produces unambiguous biochemical responses, and it is a genetic disease of the biosynthetic path rather than a deficiency of intake.
Primary CoQ10 deficiency covers mutations in the biosynthetic pathway itself. Berardo and Quinzii review the infantile multisystem forms and the diagnostic gains from exome and genome sequencing [12].
Response depends on the organ in that file. Kidney phenotypes and encephalopathic forms do not move the same way [12]. This page does not quote those protocols.
That split is informative for everything above it. The same molecule reaches one target organ and not another, in the disease it was made for. Delivery rather than a weigh-out is the binding constraint. The unchanged brain concentrations in lifelong rodent supplementation point at the same barrier [2].
Homologues and the Q9 neighbour
CoQ10 is the ten-isoprene human homologue. Rodents run mostly CoQ9. That is why Lönnrot reported both species [2]. A method that only watches the Q10 ion will miss the rodent-dominant pool.
Mass splits that matter
Each isoprene unit is 68 Da. CoQ9 sits 68 Da below CoQ10. CoQ8 sits 136 Da below. Fermentation lots can carry a shorter homologue as a process neighbour. Synthetic lots can carry cis isomers of the same chain length.
A certificate that reports “ubiquinone” without a homologue ion has named a family. Write CoQ10 and the 863.3 line, or write the Q9 ion if that is what the flask holds.
Why the rodent brain result is a homologue result too
If a rat brain holds Q9 and the feed is Q10, a null on brain Q10 can mean the organ did not take the feed. It can also mean the organ kept using its own Q9. Lönnrot measured both and both stayed flat in heart, kidney and brain [2]. That closes the easy escape.
A cell line from a human donor uses CoQ10. A rat hepatocyte uses Q9. Do not treat a Q10 spike in a rat dish as a copy of a human-tissue experiment without naming the homologue.
How to read a CoQ10 study
Four questions separate the papers that mean something from the ones that measure convenience.
Plasma or tissue?
Plasma responds reliably and tissue mostly does not [2][15]. A study reporting a rise in circulating concentration has demonstrated absorption, not delivery.
Which formulation?
Crystalline and solubilised preparations differ severalfold in plasma response [3][11]. Two experiments at the same milligram weigh-out are not comparable unless the preparation matches.
Oxidised or reduced on the label?
About 95% of circulating material is already ubiquinol whichever form goes in [3]. Dispersion is the variable that changes plasma response. Colour on receipt still tells you if a reduced lot has oxidised.
Who funded and who wrote it?
Several key reviews come from manufacturers, disclosed in the papers themselves [11]. The underlying biochemistry is independent of that, and specific bioavailability multipliers deserve more scrutiny.
Verifying research material
A crystalline, air-sensitive, light-sensitive lipid raises analytical questions that a water-soluble compound does not.
Identity
HPLC with ultraviolet or electrochemical detection is the standard assay, and both forms have distinct signatures. Ubiquinone absorbs strongly near 275 nm and ubiquinol does not, which makes the redox state directly measurable rather than inferred.
Mass spectrometry separates the homologues. CoQ9 differs from CoQ10 by a single isoprene unit and 68 Da, and it is the plausible contaminant in material of fermentation origin.
Colour is a crude but real first check. Oxidised material is a distinctive orange-yellow, and reduced material is close to white, so a preparation sold as ubiquinol that arrives orange has oxidised. Note the redox state before the mass. A yellow lot sold as ubiquinol has already failed that line.
Intact mass 863.3 average and 862.6839 monoisotopic close the carbon count. They do not close the isomer. The all-trans configuration is the biologically relevant one.
Purity and form
Chromatographic purity and redox composition are separate questions, and a certificate should report both.
Fermentation-derived material is all-trans by construction, while synthetic routes can produce cis isomers, so origin belongs on the certificate alongside purity.
Residual solvents matter more than usual here. Recrystallisation and solubilisation both involve organic solvents, and a compound this lipophilic retains them more readily than a polar solid.
Handling
Keep the solid cold, dry and dark, and keep containers sealed against air.
Light degrades the quinone and oxygen converts ubiquinol back to ubiquinone. Amber glass under inert headspace is the sensible default for the reduced form, which will otherwise oxidise during ordinary handling.
Storage guidance is a house recommendation. Analytical documentation is per-lot release testing.
Solution preparation is the practical obstacle. The compound will not dissolve in aqueous buffer at useful concentrations. Cell work therefore needs a carrier. Record the carrier in the methods rather than in a footnote.
A DMSO stock of CoQ10 will crash if you dilute it straight into cold buffer. Warm the receiving medium. Add the stock while stirring. Check for orange flecks. Those flecks are crystals, and crystals do not enter cells.
Ubiquinol stocks oxidise in the same window. If the assay needs the hydroquinone, prepare it under inert gas and use it the same day. A yellow shift is the cheap visual that the lot has gone back to CoQ10.
Kimera publishes third-party certificates of analysis for every lot in its COA database. Laboratories source CoQ10 as a mitochondrial electron carrier reference. It appears alongside methylene blue, which acts as an alternative electron carrier by a different route. It also pairs with NAD+ and glutathione where redox chemistry is the shared theme. Related work appears in the redox and cofactors category.
Common questions about CoQ10
Why is a weigh-out so large for such a small effect on tissue? Hydrophobicity. With a logP near 19, absorption is poor, saturable, and heavily dependent on formulation [3][11].
Is ubiquinol better than ubiquinone as chemistry? About 95% of circulating material is already ubiquinol regardless of what was ingested [3]. Dispersion is the variable that changes plasma response.
Does supplementation raise tissue concentration? Mostly no in the papers this page uses. Lifelong rodent dosing left heart, kidney and brain unchanged [2]. An indexed adult biopsy paper asked the muscle question and stays in the list [15].
Does this page report statin-symptom or heart-failure outcomes? No. Those files remain cited. This profile stops at chemistry, rodent tissue and lot checks.
Does the age-related decline claim hold up as tissue chemistry? It is traceable. Kalén and colleagues measured ubiquinone across organs and found a peak near age 20 followed by continuous decline [1].
How do you tell CoQ9 from CoQ10? Sixty-eight daltons and one isoprene unit. Mass spectrometry splits them. A fermentation lot can carry Q9 as a neighbour.
Summary of the evidence
Identity: C59H90O4, 863.3 g/mol, CAS 303-98-0. A benzoquinone head on a ten-unit isoprenoid tail, with a calculated logP of 19.4.
Function: the shared entry point through which electrons from many pathways reach complex III, plus a lipid-phase antioxidant role in its reduced form [16].
Absorption: saturable and formulation-dominated, with efficiency falling as the weigh-out rises [3]. Crystal dispersion dominates the formulation effect [11].
Redox form: roughly 95% of circulating material is ubiquinol whichever form is ingested [3].
Tissue: plasma and liver rose several fold in lifelong rodent supplementation while heart, kidney and brain did not [2]. Indexed adult muscle work stays in the list [15].
Indexed statin, cardiac and Parkinson papers exist. This page does not quote their endpoints.
Clearest biochemical split: primary genetic deficiency, where organs do not respond alike [12].
Write the name, the mass and the redox state on the first notebook line. CoQ10 means 863.3 Da and the quinone unless the certificate says ubiquinol. A later reader should match the lot to the chromatogram without asking which homologue sat in the vial. If a methods section names CoQ10 and then quotes a Q9 ion, stop. That run used a different reagent. Keep the certificate next to the notebook for that CoQ10 lot.
Status: supplied for laboratory research use only.
References
- Kalén A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids. 1989;24(7):579-584. PMID 2779364. DOI
- Lönnrot K, Holm P, Lagerstedt A, Huhtala H, Alho H. The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice. Biochem Mol Biol Int. 1998;44(4):727-737. PMID 9584986. DOI
- Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7 Suppl:S78-S88. PMID 17482886. DOI
- Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol. 2013;167(5):1860-1866. PMID 22626835. DOI
- Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649. PMID 25282031. DOI
- Parkinson Study Group QE3 Investigators; Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552. PMID 24664227. DOI
- Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24-34. PMID 25440725. DOI
- Oleck S, Ventura HO. Coenzyme Q10 and utility in heart failure: just another supplement? Curr Heart Fail Rep. 2016;13(4):190-195. PMID 27333901. DOI
- Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(19):e009835. PMID 30371340. DOI
- Derosa G, D’Angelo A, Maffioli P. Coenzyme Q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. Drug Des Devel Ther. 2019;13:3647-3655. PMID 31695332. DOI
- Mantle D, Dybring A. Bioavailability of coenzyme Q10: an overview of the absorption process and subsequent metabolism. Antioxidants (Basel). 2020;9(5):386. PMID 32380795. DOI
- Berardo A, Quinzii CM. Redefining infantile-onset multisystem phenotypes of coenzyme Q10-deficiency in the next-generation sequencing era. J Transl Genet Genom. 2020;4:22-35. PMID 33426503. DOI
- Wei H, Xin X, Zhang J, Xie Q, Naveed M, Kaiyan C, Xiao P. Effects of coenzyme Q10 supplementation on statin-induced myopathy: a meta-analysis of randomized controlled trials. Ir J Med Sci. 2022;191(2):719-725. PMID 33999383. DOI
- Claxton L, Simmonds M, Beresford L, Cubbon R, Dayer M, Gottlieb SS, et al. Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation. Health Technol Assess. 2022;26(4):1-128. PMID 35076012. DOI
- Dohlmann TL, Kuhlman AB, Morville T, Dahl M, Asping M, Orlando P, et al. Coenzyme Q10 supplementation in statin treated patients: a double-blinded randomized placebo-controlled trial. Antioxidants (Basel). 2022;11(9):1698. PMID 36139772. DOI
- Guerra RM, Pagliarini DJ. Coenzyme Q biochemistry and biosynthesis. Trends Biochem Sci. 2023;48(5):463-476. PMID 36702698. DOI
- Alarcón-Vieco E, Martínez-García I, Sequí-Domínguez I, Rodríguez-Gutiérrez E, Moreno-Herráiz N, Pascual-Morena C. Effect of coenzyme Q10 on cardiac function and survival in heart failure: an overview of systematic reviews and meta-analyses. Food Funct. 2023;14(14):6302-6311. PMID 37350565. DOI
CoQ10 is sold for laboratory research use only. Not for human consumption, nor medical, veterinary, or household uses.
Literature retrieved from PubMed.
